Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 4/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701506 | 1.00 | SGPL1 (0.40) | SGPL1CSNK1EKMT2ACETPCA1 | |
| SCHEMBL13555290 | 0.90 | CSNK1E (0.44) | SGPL1CSNK1E | |
| SCHEMBL13701507 | 0.90 | CSNK1E (0.44) | SGPL1CSNK1E | |
| SCHEMBL13701505 | 0.85 | SGPL1 (0.39) | SGPL1CSNK1EKMT2ACA1CA2 | |
| SCHEMBL13555284 | 0.83 | SGPL1 (0.48) | SGPL1CETP | |
| SCHEMBL13555288 | 0.77 | CSNK1E (0.42) | SGPL1CSNK1E | |
| SCHEMBL8965049 | 0.73 | CSNK1E (0.52) | CSNK1EKMT2ACETPCA1CA2 | |
| SCHEMBL13701509 | 0.73 | BCHE (0.34) | SGPL1CSNK1E | |
| SCHEMBL13555280 | 0.72 | SGPL1 (0.52) | SGPL1KMT2ACETP | |
| SCHEMBL15979267 | 0.72 | KMT2A (0.47) | KMT2ACA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039670-B2 | Analogs of alpha galactosyceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | SGMS1, CERS2, SGMS2 | SGPL1 174/4885CSNK1E 1149/4885KMT2A 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.